Last reviewed · How we verify
Byfavo
Byfavo is a Small molecule drug developed by Chungbuk National University Hospital. It is currently FDA-approved for Sedation. Also known as: Remimazolam.
At a glance
| Generic name | Byfavo |
|---|---|
| Also known as | Remimazolam |
| Sponsor | Chungbuk National University Hospital |
| Target | GABA A receptor alpha-2/beta-2/gamma-2, GABA A receptor alpha-3/beta-2/gamma-2, GABA A receptor alpha-5/beta-2/gamma-2 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Sedation
Common side effects
- Hypotension
- Hypertension
- Diastolic hypertension
- Systolic hypertension
- Hypoxia
- Diastolic hypotension
- Respiratory rate increased
- Bradycardia
- Tachycardia
- Nausea
- Pyrexia
- Headache
Key clinical trials
- Effect of Remimazolam and Propofol on Postoperative Delirium (NA)
- Hemodynamic Effects of Remimazolam vs Propofol During Robot-assisted Gynecologic Surgery (NA)
- Sedation During Endoscopy Using Remimazolam: Efficacy in a Novel Exploration (PHASE3)
- Comparison of Procedural Sedation in TEE (PHASE1)
- Remimazolam vs Midazolam to Reduce Delirium in Adults ≥65 Undergoing CPB Valve Surgery (PHASE4)
- Remimazolam vs. Midazolam for Sedation and Cognitive Outcomes in Orthopedic Surgery (PHASE3)
- Comparison of Hemodynamic Stability During Anesthesia Using Remimazolam and Sevoflurane in Minimally Invasive AVR (NA)
- Effect of Combined Administration of Sevoflurane and Remimazolam on Emergence (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Byfavo CI brief — competitive landscape report
- Byfavo updates RSS · CI watch RSS
- Chungbuk National University Hospital portfolio CI
Frequently asked questions about Byfavo
What is Byfavo?
Byfavo is a Small molecule drug developed by Chungbuk National University Hospital, indicated for Sedation.
What is Byfavo used for?
Byfavo is indicated for Sedation.
Who makes Byfavo?
Byfavo is developed and marketed by Chungbuk National University Hospital (see full Chungbuk National University Hospital pipeline at /company/chungbuk-national-university-hospital).
Is Byfavo also known as anything else?
Byfavo is also known as Remimazolam.
What development phase is Byfavo in?
Byfavo is FDA-approved (marketed).
What are the side effects of Byfavo?
Common side effects of Byfavo include Hypotension, Hypertension, Diastolic hypertension, Systolic hypertension, Hypoxia, Diastolic hypotension.
What does Byfavo target?
Byfavo targets GABA A receptor alpha-2/beta-2/gamma-2, GABA A receptor alpha-3/beta-2/gamma-2, GABA A receptor alpha-5/beta-2/gamma-2.
Related
- Target: All drugs targeting GABA A receptor alpha-2/beta-2/gamma-2, GABA A receptor alpha-3/beta-2/gamma-2, GABA A receptor alpha-5/beta-2/gamma-2
- Manufacturer: Chungbuk National University Hospital — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Sedation
- Also known as: Remimazolam